Balyasny Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Balyasny Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-277,500	Closed	-$12.8M	–	1376
2018 Q4	$12.8M	Buy	+277,500	New	+$17.1M	0.09%	301
2018 Q3	–	Sell	-200,000	Closed	-$16.8M	–	1627
2018 Q2	$16.8M	Buy	+200,000	New	+$17.4M	0.08%	352
2017 Q4	–	Sell	-270,000	Closed	-$18M	–	2029
2017 Q3	$18M	Buy	+270,000	New	+$16.2M	0.07%	343
2017 Q1	–	Sell	-70,000	Closed	-$2.92M	–	1565
2016 Q4	$2.92M	Buy	+70,000	New	+$3.67M	0.02%	819

Other funds holding AGIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Balyasny Asset Management's AGIO Position: Q1 2026 in Review

Balyasny Asset Management reduced its Agios Pharmaceuticals (AGIO) stake by 97% in Q1 2026, selling an estimated $17.5M and leaving 18,009 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #2275.

Balyasny Asset Management first reported a position in AGIO in Q3 2015 and has held it in 27 quarters since. The position peaked at $64.6M in Q4 2017. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

Balyasny Asset Management held 18,009 shares of Agios Pharmaceuticals worth $609K as of Q1 2026.
Balyasny Asset Management sold 617,060 Agios Pharmaceuticals shares in Q1 2026, an estimated $17.5M.
Agios Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2275 holding.
Balyasny Asset Management first reported a position in Agios Pharmaceuticals in Q3 2015 and has held it in 27 quarters since.
Balyasny Asset Management's Agios Pharmaceuticals position peaked at $64.6M in Q4 2017.
233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.